Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs composed of an antibody linked, via a chemical, to a biological active cytotoxic payload, intended to target and kill tumor cells while sparing healthy cells. Over 210 developers across the world have a clinical ADC with more than 110 different targets are being investigated at pre-clinical stage under this renaissance period of ADCs.

Kind is developing next generation ADC molecules. The clinical candidates from the ADC program will employ in-house developed proprietary linker chemistry to maximize the potentials of ADCs to treat cancers and other diseases.